Terumo (TRUMY)
(Delayed Data from OTC)
$17.43 USD
-0.22 (-1.25%)
Updated Jul 23, 2024 03:59 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
TRUMY 17.43 -0.22(-1.25%)
Will TRUMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TRUMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRUMY
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Terumo (TRUMY) Moves to Strong Buy: Rationale Behind the Upgrade
TRUMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for March 28th
New Strong Buy Stocks for March 28th
Here's What Could Help Terumo Corp. (TRUMY) Maintain Its Recent Price Strength
Other News for TRUMY
MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms
MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims
MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke
MicroVention Announces the Next Evolution in Stent Innovation: MicroVention’s LVIS™ EVO™ Intraluminal Support Device Now Available in the United States
Data-Driven Growth Fuels More Upside For Overlooked Artivion